Andera Life Sciences has announced the closing of the €456 million financing round of its BioDiscovery-6 fund.
With the now sixth generation of BioDiscovery funds, Andera Partners confirms its position as one of the leading venture capitalists for life sciences in Europe. The existing institutional investors of the BioDiscovery funds are again involved. They have been joined by new subscribers, which include funds of funds, insurance companies, pension funds, family offices, private investors and pharmaceutical companies.
Andera Life Sciences is the business unit specialized in innovative therapies and medical technologies of the investment company Andera Partners, which is based in Paris and Munich, among others.
With this new fund, the management team intends to continue its focused investment strategy focused on building a balanced portfolio of innovative companies developing therapeutics and medical technologies, at all stages of their development, in Europe and the United States. To date, BioDiscovery 6 has made six investments in Evommune, Amolyt, TargED, Tubulis, Mineralys and Imcheck.
The Andera Life Sciences team is led by five partners: Sofia Ioannidou, Olivier Litzka, Gilles Nobécourt, Jan Van den Bossche and Raphaël Wisniewski. They commented: “We are honoured by the support of our investors which is strengthening our position as one of the main players in our sector. The acceleration of our funds’ development demonstrates investors’ growing interest in financing medical innovation. For over twenty years, Andera Life Sciences’ support for companies has resulted in over twenty treatments being made available to patients and their doctors. This is the work that we wish to continue.”
The BioDiscovery 6 fund, classified as Article 8 according to the “European Sustainable Finance Disclosure Regulation (SFDR)” has ambitious targets in terms of CSR. Furthermore, it contributes to the UN Sustainable Development Goals in connection with ‘Health and Well-being’.